Expanding the Foundation for Personalized Medicine: Implications and Challenges for Dentistry

Journal of Dental Research

Volumn 92, Issue , 2013, Pages S3-S10

  Garcia, I ^a   Kuska, R ^a   Somerman, M J ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

biomarkers; diagnostics; genomics; oral diseases; pharmacogenomics; targeted therapies

Indexed keywords

BIOLOGY; BIOMARKERS; DENTAL PROCEDURE; DIAGNOSIS; DIAGNOSTIC IMAGING; GENOMICS; HUMAN; HUMAN GENOME; MOLECULARLY TARGETED THERAPY; ORAL DISEASES; PERSONALIZED MEDICINE; PHARMACOGENOMICS; REGENERATIVE MEDICINE; REVIEW; TARGETED THERAPIES;

BIOMARKERS; DIAGNOSTICS; GENOMICS; ORAL DISEASES; PHARMACOGENOMICS; TARGETED THERAPIES;

COMPUTATIONAL BIOLOGY; DENTAL CARE; DIAGNOSTIC IMAGING; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; REGENERATIVE MEDICINE;

EID: 84879178435     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034513487209     Document Type: Article

References (60)

1. Agrawal N Frederick MJ Pickering CR Bettegowda C Chang K Li RJ. (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
2. Al Kawas S Rahim ZH Ferguson DB (2012). Potential uses of human salivary protein and peptide analysis in the diagnosis of disease. Arch Oral Biol 57: 1-9.
3. Alevizos I Alexander S Turner J Illei GG (2011). MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome. Arthritis Rheum 63: 535-544.
4. Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
5. Braakhuis BJ Bloemena E Leemans CR Brakenhoff RH (2010). Molecular analysis of surgical margins in head and neck cancer: More than a marginal issue. Oral Oncol 46: 535-544.
6. Cassell A Grandis JR (2010). Investigational EGFR-targeted therapies in HNSCC. Expert Opin Investig Drugs 6: 709-722.
7. Castagnola M Cabras T Vitali A Sanna MT Messana I (2011). Biotechnological implications of the salivary proteome. Trends Biotechnol 29: 409-418.
8. Chen T Yu H Izard J Baranova O Kakshmanan A Dewhirst FE (2010). The Human Oral Microbiome Database: a Web accessible resource for investigating oral microbe taxonomic and genomic information. Database Article ID baq-013, doi:10.1093/database/baq013. Accessed on 4/1/2013 at: http://www.ncbi.nlm.nih.gov/pubmed/20624719.
9. Cohen JP (2012). Overcoming regulatory and economic challenges facing pharmacogenomics. N Biotechnol 29: 751-756.
10. Collins FS (2010). Has the revolution arrived? Nature 464: 674-675.
11. Collins FS (2011). Reengineering translational science: the time is right. Sci Transl Med 3:90cm17.
12. Czerninski R Amornphimoltham P Patel V Molinolo AA Gutkind JS (2009). Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res 2: 27-36.
13. Desmeules J Gascon MP Dayer P Magistris M (1991). Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Phamarmacol 41: 23-26.
14. Drmanac R (2011). The advent of personal genome sequencing. Genet Med 13: 188-190.
15. Elashoff D Zhou H Reiss J Wang J Xiao H Henson B. (2012). Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev 21: 664-672.
16. Elferink LA Resto VA (2011). Receptor-tyrosine-kinase-targeted therapies for head and neck cancer. J Sig Transduct 2011: 982870.
17. ENCODE Project Consortium (2007). Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799-816.
18. ENCODE Project Consortium (2012). An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74.
19. Eng G Chen A Vess T Ginsburg GS (2012). Genome technologies and personalized dental medicine. Oral Dis 18: 223-235.
20. Fackler JL McGuire AL (2009). Paving the way to personalized medicine: steps to successful implementation. Curr Pharmacogenomics Person Med 7: 125
21. Fillingim RB Slade GD Diatchenko L Dubner R Greenspan JD Knott C. (2011). Summary of findings from the OPPERA baseline case-control study: implications and future directions. J Pain 12(11 Suppl):102S-107S.
22. Floriano PN Christodoulides N Miller CS Ebersole JL Spertus J Rose BG. (2009). Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem 55: 1530-8.
23. Frueh FW Amur S Mummaneni P Epstein RS Aubert RE DeLuca TM. (2008). Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28: 992-998.
24. Gasche Y Daali Y Fathi M Chiappe A Cottini S Dayer P. (2004). Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351: 2827-2731; erratum in N Engl J Med 352:638, 2005.
25. Hamburg MA Collins FS (2010). The path to personalized medicine. N Engl J Med 363: 301-304; erratum in N Engl J Med 363:1912, 2010.
26. Hoelder S Clarke PA Workman P (2012). Discovery of small molecule cancer drugs: successes, challenges and opportunities Mol Oncol 6: 155-176.
27. Howard JD Lu B Chung CH (2012). Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation. Oral Oncol 48: 10-17.
28. Hsiao CJ Hing E Socey TC Cai B (2010). Centers for Disease Control and Prevention, National Center for Health Statistics, 2010. Division of Health Care Statistics Electronic Medical Record/Electronic Health Record Systems of Office-based Physicians: United States, 2009 and Preliminary 2010 Estimates. Accessed on 4/1/2013 at: http://www.cdc.gov/nchs/data/hestat/emr_ehr_09/emr_ehr_09.pdf
29. Kolenbrander PE Andersen RN Blehert DS Egland PG Foster JS Palmer RJ Jr (2002). Communication among oral bacteria. Microbiol Mol Biol Rev 66: 486-505.
30. Liu C Worthington RJ Melander C Wu H (2011). A new small molecule specifically inhibits the cariogenic bacterium Streptococcus mutans in multispecies niofilms. Antimicrob Agents Chemother 55: 2679-2687.
31. Manolio TA Chisholm RL Ozenberger B Roden DM Williams MS Wilson R. (2013). Implementing genomic medicine in the clinic: the future is here. Genet Med 15: 258-267.
32. Maixner W Greenspan JD Dubner R Bair E Mulkey F Miller V. (2011). Potential autonomic risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. J Pain 12(11 Suppl):75S-91S.
33. Malamud D (1992). Saliva as a diagnostic fluid. BMJ 305: 207-208.
34. Malamud D (2011). Saliva as a diagnostic fluid. Dent Clin North Am 55: 159-178.
35. McCarty CA Chisholm RL Chute CG Kullo IJ Jarvik GP Larson EB, eMERGE Team et al. (2011). The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 4: 13.
36. Mendonça EA (2004). Clinical decision support systems: perspectives in dentistry. J Dent Educ 6: 589-597.
37. Miller CS Foley JD Bailey AL Campell CL Humphries RL Christodoulides N. (2010). Current developments in salivary diagnostics. Biomark Med 4: 171-189.
38. Milne CP (2010). Personalized medicine is playing a growing role in developmental pipelines. Tufts Center for the Study of Drug Development Impact Report 12: 6.
39. National Institute of Dental and Craniofacial Research (NIDCR). (2010). Rapamycin therapy in head and neck squamous carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). [cited 2013 Feb 14]. Accessed on 4/1/2013 at: http://www.clinicaltrials.gov/ct2/show/NCT01195922 NLM Identifier NCT01195922
40. National Institutes of Health (2012). A study of genetic variation influencing pain and response to opioid medications in patients with chronic pain. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US): Stanford University. Accessed on 4/1/2013 at: http://www.clinicaltrials.gov/ct2/show/record/NCT01293994. NLM Identifier NCT01293994.
41. Personalized Medicine Coalition (2010). The case for personalized medicine. 3rd ed. Accessed on 4/1/2013 at: http://www.personalizedmedicinecoalition.org/sites/default/files/files/Case_for_PM_3rd_edition.pdf
42. Recchiuti A Serhan CN (2012). Pro-resolving lipid mediators (SPMs) and their actions in regulating miRNA in novel resolution circuits in inflammation. Front Immunol 3: 298.
43. Rothenberg SM Ellisen LW (2012). The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest 122: 1951-1957.
44. Rudman W Hart-Hester S Jones W Caputo N Madison M (2010). Integrating medical and dental records: a new frontier in health information management. J AHIMA [American Health Information Management Association] 81: 36-39.
45. Scanlon CS Van Tubergen EA Inglehart RC D'Silva NJ (2013). Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent Res 92: 114-121.
46. Scheuner MT Sieverding P Shekelle PG (2008). Delivery of genomic medicine for common chronic adult diseases: a systematic review. J Am Med Assoc 299: 1320-1334.
47. Schleyer T Thyvalikakath TP Spallek H Dziabiak MP Johnson LA (2012). From information technology to informatics: the information revolution in dental education. J Dent Educ 76: 143-153.
48. Schleyer T Song M Gilbert GH Rindal DB Fellows JL Gordan VV. (2013). Electronic dental record use and clinical information management patterns among practitioner-investigators in the Dental Practice-based Research Network. J Am Dent Assoc 144: 49-58.
49. Shaffer JR Feingold E Wang X Tcuenco KT Weeks DE DeSensi RS. (2012). Heritable patterns of tooth decay in the permanent dentition: principal components and factor analyses. BMC Oral Health 12: 7.
50. Siegel R Naishadham D Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
51. Slootweg PJ Hordijk GJ Schade Y van Es RJ Koole R (2002). Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol 38: 500-503.
52. Stransky N Egloff AM Tward AD Kostic AD Cibulskis K Sivachenko A. (2011). The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
53. Tanner AC Mathney JM Kent RL Chalmers NI Hughes CV Loo CY. (2011a). Cultivable anaerobic microbiota of severe early childhood caries. J Clin Microbiol 49: 1464-1474.
54. Tanner AC Kent RL Jr Holgerson PL Hughes CV Loo DY Pradhan N. (2011b) Microbiota of severe early childhood caries before and after therapy. J Dent Res 90: 1298-1305.
55. US Department of Energy, Office of Science. White House press release, June 26, 2000. Accessed on 4/1/2013 at: http://www.ornl.gov/sci/techresources/Human_Genome/project/clinton2.shtml.
56. US Food and Drug Administration (2012). FDA Table of Pharmacogenomic Biomarkers in Drug Labels. Accessed on 4/1/2013 at: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
57. US Government Printing Office (2008). P.L. 100-233 122 Stat. 881. May 21, 2008. Accessed on 4/1/2013 at: http://www.gpo.gov/fdsys/pkg/PLAW-110publ233/pdf/PLAW-110publ233.pdf
58. Valm AM Mark Welch JL Rieken CW Hasegawa Y Sogin ML Oldenbourg R. (2011). Systems level analysis of microbial community organization through combinatorial labeling and spectral imaging. Proc Natl Acad Sci USA 108: 4152-4157.
59. Weigum SE Floriano PN Redding SW Yeh CK Westbrook SD McGuff HS. (2010). Nano-Bio-Chip sensor platform for examination of oral exfoliative cytology. Cancer Prev Res 3: 518-528.
60. Wendell S Wang X Brown M Cooper ME DeSensi RS Weyant RJ. (2010). Taste genes associated with dental caries. J Dent Res 89: 1198-1202.